Better outcomes in babies with bacterial meningitis
| ISRCTN | ISRCTN17216564 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN17216564 |
| Integrated Research Application System (IRAS) | 1013356 |
| Sponsor | City St George's, University of London |
| Funders | Health Technology Assessment Programme, Canadian Institutes of Health Research |
- Submission date
- 22/04/2026
- Registration date
- 06/07/2026
- Last edited
- 05/10/2026
- Recruitment status
- Recruiting
- Overall study status
- Ongoing
- Condition category
- Nervous System Diseases
Plain English summary of protocol
Background and study aims
Meningitis is an infection around the brain and spinal cord. In babies under 3 months, even with antibiotics around 1 in 20 die and 1 in 3 survivors have lifelong disabilities. In older children, steroids given with antibiotics reduce some harm, but it is not known whether this also helps young babies. The aim of this study is to determine whether giving dexamethasone to babies with suspected or confirmed bacterial meningitis improves survival and reduces long-term problems.
Who can participate?
Babies up to 3 months of age who doctors think have bacterial meningitis.
What does the study involve?
Babies will be randomly allocated to receive dexamethasone or standard care shortly after starting antibiotics. Because bacterial meningitis is an emergency, babies may be enrolled into the trial before parents are approached, using a deferred consent model. Parents will usually be approached within 48 hours, provided with information about the study, and asked for consent for their baby’s ongoing participation and follow-up until 2 years of age.
Parents may withdraw their baby at any time without affecting their care. If a baby is later found not to have bacterial meningitis, study treatment will be stopped.
Parents will be asked to complete questionnaires at hospital discharge and at 12 and 24 months. Information from medical records will also be collected. Outcomes include survival and developmental difficulties such as deafness, reduced vision, seizures, cerebral palsy and learning problems.
What are the possible benefits and risks of participating?
The trial addresses uncertainty about whether dexamethasone improves survival and long-term outcomes in babies with bacterial meningitis and may help improve future treatment.
As bacterial meningitis is an emergency, treatment must start quickly. Based on advice from parents with experience of bacterial meningitis in their baby, the trial uses deferred consent so that treatment is not delayed and parents are not overburdened during a critical situation. Parents are approached as soon as clinically appropriate by trained staff, usually within 48 hours, to discuss the study and provide written informed consent for ongoing participation.
Dexamethasone is commonly used in babies for inflammatory conditions and is recommended for older children with meningitis, although like all medicines it can cause side effects. Potential short-term risks include raised blood glucose and, rarely, gastrointestinal bleeding. Babies will be closely monitored throughout their care.
To minimise risks, very preterm babies (<34 weeks) are excluded from receiving dexamethasone during the first week of life, treatment is stopped if bacterial meningitis becomes unlikely, and all serious events are reviewed by the trial team and an independent data monitoring committee. Parents and charities helped design the study and continue to advise on the trial.
Where is the study run from?
The National Perinatal Epidemiology Unit Clinical Trials Unit (NPEU CTU) at the University of Oxford, England, UK, in partnership with City St George’s, University of London, sponsor for the UK sites, and the University of British Columbia, sponsor for the Canadian sites, are coordinating and managing the study.
When is the study starting and how long is it expected to run for?
The total planned trial period is 1 September 2025 to 31 August 2033, with recruitment planned from 1 June 2026 to 30 November 2030
Who is funding the study?
Health Technology Assessment Programme (UK) and Canadian Institutes of Health Research (Canada)
Who is the main contact?
Vasha Bari, bobbi@npeu.ox.ac.uk
Contact information
Scientific, Public
New Radcliffe House, Radcliffe Observatory Quarter
Oxford
OX2 6NW
United Kingdom
| Phone | +44 (0)1865 289437 |
|---|---|
| bobbi@npeu.ox.ac.uk |
Principal investigator
Tooting Campus, Cranmer Terrace
London
SW17 0RE
United Kingdom
| pheath@sgul.ac.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | Randomized controlled trial |
| Masking | Open (masking not used) |
| Control | Active |
| Assignment | Single |
| Purpose | Treatment, Efficacy |
| Scientific title | Better Outcomes in Babies with Bacterial meningitis (BOBBi) – a multisite, open-label, two-arm, parallel-group, pragmatic, randomised controlled trial to compare dexamethasone versus no dexamethasone as treatment in babies with suspected or confirmed bacterial meningitis |
| Study acronym | BOBBi |
| Study objectives | The aim of the trial is to find out whether giving a short course of steroids (dexamethasone) alongside usual antibiotic treatment helps more babies from 32+0 corrected gestational weeks up to and including 3 months’ corrected age (babies born at term (37+0 or greater) may be randomised until 3 months from their birth date) with suspected or confirmed bacterial meningitis survive without long-term difficulties. We will also look at how these babies are developing as they grow, to see if steroids have any longer-term effects. 1. How the babies are developing at 2 years of age (for example, movement, hearing, vision and learning) 2. The child’s and family’s quality of life 3. Any side effects of the steroids and how often babies need to come back to hospital or see other services (In England, newborn hearing screen results may be obtained via the newborn screening programme [NHSP]) |
| Ethics approval(s) |
Approved 06/07/2026, South Central – Oxford A Research Ethics Committee (Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8241; oxforda.rec@hra.nhs.uk), ref: 26/SC/0146 |
| Health condition(s) or problem(s) studied | Bacterial meningitis (BM) |
| Intervention | Babies will be randomised 1:1 using a centralised randomisation system. Intervention arm: Dexamethasone 0.15 mg/kg administered intravenously every 6 hours (total daily dose 0.6 mg/kg) for 4 days (16 doses), given alongside treatment-as-usual based on national clinical guidelines. Dexamethasone is started within 12 hours of the first antibiotic dose for suspected or confirmed bacterial meningitis and will be stopped if a virus is identified as the sole cause of meningitis, or if antibiotics are stopped. Comparator arm: Treatment-as-usual based on national clinical guidelines without dexamethasone. All babies will receive standard antibiotic therapy and supportive care. Follow-up includes in-hospital outcomes and parent-completed questionnaires at 12 and 24 months of age. |
| Intervention type | Drug |
| Phase | Phase III |
| Drug / device / biological / vaccine name(s) | Dexamethasone |
| Primary outcome measure(s) |
Survival without moderate or severe neurodevelopmental impairment at 24 months of age corrected for prematurity in preterm babies, and 24 months actual age in term babies, assessed using parent-completed questionnaires with additional review of routine clinical follow-up information by a blinded endpoint review committee. |
| Key secondary outcome measure(s) |
1. Total number of days spent in critical care - number of days of neonatal intensive care (defined as per national standards, indicated in the Country-specific Annex), number of days of paediatric intensive care (defined as per national standards, indicated in the Country-specific Annex (timepoint: between randomisation and hospital discharge (with an upper limit of 8 weeks from randomisation)) |
| Completion date | 31/08/2033 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Mixed |
| Lower age limit | 0 Months |
| Upper age limit | 3 Months |
| Sex | All |
| Target sample size at registration | 965 |
| Total final enrolment | 1123 |
| Key inclusion criteria | 1. Babies must fulfil one of the following age-based criteria: 1.1. Babies born at ≥ 37+0 gestational weeks: 1.1.1. Up to and including 3 months from their birth date OR 1.2. Babies born at 34+0 to 36+6 gestational weeks: 1.2.1. Up to and including 3 months corrected age OR 1.3. Babies born less than 34+0 gestational weeks: 1.3.1. Are between 32+0 corrected gestational weeks and 3 months corrected age inclusive AND 1.3.2. Are older than 7 days of age 2. Planned or initiated treatment with antibiotics for suspected or confirmed bacterial meningitis based on having one or more of the following three clinical and/or laboratory features: 2.1. Seizures or bulging fontanelle or altered consciousness (coma) 2.2. Blood C-Reactive Protein (CRP) ≥20 mg/L* AND one or more of: 2.2.1. Raised cerebrospinal fluid (CSF) white cell count (>20/mm3 for neonates ≤28 days post birth; >5/mm3 for babies >28 days post birth)** 2.2.2. CSF protein ≥0.8 g/L** 2.2.3. CSF/blood glucose ratio <0.5 3. Positive CSF Gram stain OR positive CSF polymerase chain reaction (PCR) for a relevant bacterium OR CSF culture for a relevant bacterium *If CRP is not available then an abnormal procalcitonin (PCT) threshold may be used instead (i.e., ≥0.5 mg/dL) **When interpreting the results of cerebrospinal fluid (CSF) investigations, take into account red cells in the sample, which may suggest blood contamination or a different diagnosis. In the case of blood contamination if the CSF RBC count is >=1000 cells/µL then CSF WBC and CSF protein should be adjusted - subtract 1 WBC per 500 RBCs - subtract 0.01 g/l protein per 1000 RBCs |
| Key exclusion criteria | 1. Where the randomisation cannot occur within 12 hours of the first administration of antibiotics for meningitis, or within 12 hours of the first administration of changed dose/type of antibiotics where antibiotics have been changed in dose or type for newly suspected or confirmed meningitis 2. Previous neurosurgical intervention or shunt 3. Known hypersensitivity to dexamethasone or any of its excipients 4. Previous randomisation into this trial |
| Date of first enrolment | 09/10/2026 |
| Date of final enrolment | 30/11/2030 |
Locations
Countries of recruitment
- United Kingdom
- England
- Northern Ireland
- Scotland
- Wales
- Canada
Study participating centres
-
-
England
-
-
Canada
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan | The datasets generated during and/or analysed during the current study will be available upon reasonable request from the chief investigator Prof. Paul Heath (pheath@citystgeorges.ac.uk). De-identified participant data underlying the results reported in the main publications will be made available after publication of the primary results and will remain available for a defined period thereafter, subject to review and approval of a data access request. Data will be shared with researchers for the purpose of secondary analyses, following review by the trial team and completion of a data sharing agreement. All data will be fully de-identified prior to sharing, and access will be provided in accordance with participant consent and applicable ethical, legal and regulatory requirements. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol file | version 1.0 | 15/04/2026 | 05/10/2026 | No | No |
Additional files
- ISRCTN17216564_Protocol_V1.0_15Apr2026.pdf
- Protocol file
Editorial Notes
05/10/2026: Protocol uploaded. The date of first enrolment was changed from 04/10/2026 to 09/10/2026.
07/07/2026: ISRCTN received notification of combined HRA/MHRA approval for this trial on 07/07/2026.
22/04/2026: Study's existence confirmed by the HRA.